AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32070681 — intervention group
Group type: EXPERIMENTAL
Intervention: ART-Immed/40w (initiating ART immediately upon enrolment, interrupted at 40 weeks)
Number of subjects: 0
Study 32070681 — intervention group
Group type: EXPERIMENTAL
Intervention: ART-Immed/96w (initiating ART immediately upon enrolment, interrupted at 96 weeks)
Number of subjects: 0
Study 32070681 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose of PCV7 or HibCV at 15 months of age
Number of subjects: 0
Study 32070681 — intervention group
Group type: COMPARATOR
Intervention: HIV-unexposed children
Number of subjects: 0
Study 32070681 — intervention group
Group type: COMPARATOR
Intervention: HEU (HIV-exposed uninfected) children
Number of subjects: 0
Study 34042412 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-wave diathermy (SWD) treatment
Number of subjects: 42
Study 34042412 — intervention group
Group type: COMPARATOR
Intervention: Placebo SWD treatment (Control)
Number of subjects: 42
Study 33596959 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoiding routine drain placement (experimental arm)
Number of subjects: 404
Study 33596959 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic drain placement (control arm)
Number of subjects: 404
Study 33596959 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall morbidity and mortality (secondary endpoint)
Number of subjects: 404
Study 33596959 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive Complications Index (secondary endpoint)
Number of subjects: 404
Study 33596959 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence and time for diagnosis of anastomotic and duodenal leaks (secondary endpoint)
Number of subjects: 404
Study 33596959 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of hospital stay (secondary endpoint)
Number of subjects: 404
Study 33596959 — intervention group
Group type: EXPERIMENTAL
Intervention: Readmission rate (secondary endpoint)
Number of subjects: 404
Study 32507842 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologic intervention for hyperlipidaemia with LDL-C level of 3.36 mmol/l (130 mg/dl) as the threshold.
Number of subjects: 16
Study 32507842 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologic intervention for hyperglycaemia with fasting plasma glucose of ≥5.3 mmol/l (95 mg/dl) and 2-hour postprandial glucose level of 7.8 mmol/l (140 mg/dl) as the threshold.
Number of subjects: 16
Study 32507842 — intervention group
Group type: EXPERIMENTAL
Intervention: Initiating treatment for hypertension at blood pressure of ≥130/≤89 mmHg or ≤139/≥85 mmHg.
Number of subjects: 16
Study 32507842 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologic intervention for hypertensive patients (BP ≥160/≥100 mmHg) with total cholesterol of 6.5 mmol/l (251.35 mg/dl) or higher.
Number of subjects: 16
Study 36171728 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrument-Assisted Soft Tissue Mobilization (IASTM)
Number of subjects: 26
Study 36171728 — intervention group
Group type: COMPARATOR
Intervention: Muscle Energy Technique (MET)
Number of subjects: 26
Study 33993064 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone therapy (TTh) for 2 years
Number of subjects: 0
Study 33993064 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle intervention alone
Number of subjects: 0
Study 33844568 — intervention group
Group type: EXPERIMENTAL
Intervention: ACH + CM
Number of subjects: 21
Study 33844568 — intervention group
Group type: COMPARATOR
Intervention: ACH alone
Number of subjects: 21
Study 32107288 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment (ET)
Number of subjects: 152
Study 32107288 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful recanalization (defined as modified Thrombolysis in Cerebral Infarction Score, mTICI 2b/3)
Number of subjects: 152
Study 32107288 — intervention group
Group type: EXPERIMENTAL
Intervention: Age <70 years
Number of subjects: 152
Study 32107288 — intervention group
Group type: EXPERIMENTAL
Intervention: NIHSS <12
Number of subjects: 152
Study 32107288 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher age, pre‐stroke MRS score >1, failed recanalization
Number of subjects: 152
Study 33739957 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 70
Study 33739957 — intervention group
Group type: COMPARATOR
Intervention: Milrinone
Number of subjects: 70
Study 32248629 — intervention group
Group type: EXPERIMENTAL
Intervention: FM 2016 criteria
Number of subjects: 2531
Study 32248629 — intervention group
Group type: COMPARATOR
Intervention: AAPT criteria
Number of subjects: 2531
Study 32248629 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician diagnosed fibromyalgia
Number of subjects: 2531
Study 35589454 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal justice-only writing intervention
Number of subjects: 0
Study 35589454 — intervention group
Group type: EXPERIMENTAL
Intervention: Justice writing conditions
Number of subjects: 0
Study 35589454 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive injustice writing intervention
Number of subjects: 0
Study 35589454 — intervention group
Group type: COMPARATOR
Intervention: Neutral writing condition (control)
Number of subjects: 0
Study 33390060 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic and Health Survey questionnaire
Number of subjects: 0
Study 33390060 — intervention group
Group type: COMPARATOR
Intervention: Questionnaire incorporating an event history calendar, recall cues, and increased probing strategies
Number of subjects: 0
Study 32551725 — intervention group
Group type: EXPERIMENTAL
Intervention: Group therapy
Number of subjects: 108
Study 32551725 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual therapy
Number of subjects: 108
Study 32551725 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonimprovers
Number of subjects: 108
Study 36454721 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of fan when air cleaner was on low setting
Number of subjects: 2
Study 36454721 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of air cleaner on high setting (compared to low) when fan was off
Number of subjects: 2
Study 33839076 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan (0.075 to 0.1 ug/kg/min for 24 h, once weekly for 6 weeks)
Number of subjects: 44
Study 33839076 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 35760340 — intervention group
Group type: EXPERIMENTAL
Intervention: Loaner Digital Device (Bluetooth enabled iPad with data plan coverage)
Number of subjects: 90
Study 35760340 — intervention group
Group type: EXPERIMENTAL
Intervention: Loaner Digital Device + Coaching Support (loaner device plus up to six, 15–20 min motivational interviewing‐based coaching calls)
Number of subjects: 90
Study 35760340 — intervention group
Group type: COMPARATOR
Intervention: Control Condition (no additional study intervention)
Number of subjects: 90
Study 33821578 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term PDE5Is
Number of subjects: 109
Study 33821578 — intervention group
Group type: COMPARATOR
Intervention: Not on PDE5Is
Number of subjects: 109
Study 34585254 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular surgery
Number of subjects: 125
Study 34585254 — intervention group
Group type: COMPARATOR
Intervention: Non-vascular surgery
Number of subjects: 125
Study 33938917 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative management
Number of subjects: 5179
Study 33938917 — intervention group
Group type: COMPARATOR
Intervention: Invasive management
Number of subjects: 5179
Study 36113908 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure-based treatment for perfectionism (ETP)
Number of subjects: 71
Study 36113908 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (WL)
Number of subjects: 71
Study 34543257 — intervention group
Group type: EXPERIMENTAL
Intervention: Cap-assisted technique
Number of subjects: 342
Study 34543257 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique
Number of subjects: 342
Study 35549944 — intervention group
Group type: EXPERIMENTAL
Intervention: SEMS group (self-expanding metallic stents)
Number of subjects: 87
Study 35549944 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SEMS)
Number of subjects: 87
Study 34061467 — intervention group
Group type: EXPERIMENTAL
Intervention: New CLL score including CD43 and CD180
Number of subjects: 237
Study 35241051 — intervention group
Group type: EXPERIMENTAL
Intervention: Amine fluoride toothpaste (1400 ppmF)
Number of subjects: 120
Study 35241051 — intervention group
Group type: COMPARATOR
Intervention: Sodium monofluorophosphate toothpaste (1450 ppmF)
Number of subjects: 120
Study 33407337 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular injection of Hyaluronic acid after arthroscopic lateral release.
Number of subjects: 90
Study 33407337 — intervention group
Group type: COMPARATOR
Intervention: Arthroscopic lateral release only (Control Group B).
Number of subjects: 90
Study 35666545 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose topical dexamethasone
Number of subjects: 0
Study 35666545 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34685778 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone treatment (verum)
Number of subjects: 386
Study 34685778 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (control)
Number of subjects: 386
Study 35002984 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 100
Study 35002984 — intervention group
Group type: COMPARATOR
Intervention: Control (no metformin therapy)
Number of subjects: 100
Study 35002984 — intervention group
Group type: COMPARATOR
Intervention: Control (GA improved subgroup)
Number of subjects: 100
Study 35002984 — intervention group
Group type: COMPARATOR
Intervention: Control (GA unimproved subgroup)
Number of subjects: 100
Study 32151500 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromobilization exercise program (NEP)
Number of subjects: 30
Study 32151500 — intervention group
Group type: COMPARATOR
Intervention: Standard care group
Number of subjects: 30
Study 32342892 — intervention group
Group type: EXPERIMENTAL
Intervention: DSS with 100% reliability
Number of subjects: 36
Study 32342892 — intervention group
Group type: COMPARATOR
Intervention: DSS with 90% reliability
Number of subjects: 36
Study 32342892 — intervention group
Group type: COMPARATOR
Intervention: DSS with 80% reliability
Number of subjects: 36
Study 32342892 — intervention group
Group type: COMPARATOR
Intervention: DSS with undisclosed reliability
Number of subjects: 36
Study 33078322 — intervention group
Group type: EXPERIMENTAL
Intervention: Menghini-type needle (needle M)
Number of subjects: 97
Study 33078322 — intervention group
Group type: COMPARATOR
Intervention: Conventional needle (needle S)
Number of subjects: 97
Study 33078322 — intervention group
Group type: EXPERIMENTAL
Intervention: Both needles
Number of subjects: 97
Study 33272368 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg once daily for 12 weeks
Number of subjects: 70
Study 33272368 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 35837707 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab (short-course, varying from 3 to 6 doses)
Number of subjects: 0
Study 35837707 — intervention group
Group type: COMPARATOR
Intervention: Denosumab
Number of subjects: 0
Study 35837707 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonate-loaded bone cement
Number of subjects: 0
Study 35837707 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous microwave ablation and bisphosphonate-loaded polymethylmethacrylate cementoplasty
Number of subjects: 0
Study 33492894 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Intervention Group
Number of subjects: 0
Study 33492894 — intervention group
Group type: COMPARATOR
Intervention: Usual Care Group
Number of subjects: 0
Study 35910056 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 IU hCG
Number of subjects: 174
Study 35910056 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 IU hCG
Number of subjects: 174
Study 35910056 — intervention group
Group type: COMPARATOR
Intervention: Control (no hCG)
Number of subjects: 174
Study 32524511 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led medicines optimisation clinic
Number of subjects: 62
Study 32524511 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 62
Study 35553286 — intervention group
Group type: EXPERIMENTAL
Intervention: Healer-delivered counseling and point-of-care HIV tests
Number of subjects: 173
Study 35553286 — intervention group
Group type: COMPARATOR
Intervention: Referral for clinic-based testing
Number of subjects: 173
Study 32876737 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D viewing mode
Number of subjects: 0
Study 32876737 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D viewing mode
Number of subjects: 0
Study 32876737 — intervention group
Group type: COMPARATOR
Intervention: 2D → 2D
Number of subjects: 0
Study 32876737 — intervention group
Group type: COMPARATOR
Intervention: 3D → 3D
Number of subjects: 0
Study 32599336 — intervention group
Group type: EXPERIMENTAL
Intervention: Late preterm children
Number of subjects: 652
Study 32599336 — intervention group
Group type: COMPARATOR
Intervention: Term children
Number of subjects: 652
Study 35674762 — intervention group
Group type: EXPERIMENTAL
Intervention: Trifarotene 0.005% cream
Number of subjects: 0
Study 34254673 — intervention group
Group type: EXPERIMENTAL
Intervention: Cenobamate (median dose 200 mg, range 50–400 mg)
Number of subjects: 149
Study 34254673 — intervention group
Group type: EXPERIMENTAL
Intervention: Cenobamate
Number of subjects: 149
Study 35063186 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation (DBS) with personalized stimulation parameters based on intracranial recordings
Number of subjects: 1
Study 35063186 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 1
Study 33676560 — intervention group
Group type: COMPARATOR
Intervention: Standard routine care
Number of subjects: 750
Study 33676560 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural nudges (text messages) along with the use of a social media platform
Number of subjects: 750
Study 33676560 — intervention group
Group type: EXPERIMENTAL
Intervention: Midwife-led continuity care involving individualised teleconferencing sessions
Number of subjects: 750
Study 33040465 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF/FTC plus vitamin D3 and calcium supplementation (400 units of vitamin D3 and 1200 mg of elemental calcium/day)
Number of subjects: 100
Study 33040465 — intervention group
Group type: COMPARATOR
Intervention: TDF/FTC only
Number of subjects: 100
Study 33040465 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF/FTC plus vitamin D3 and calcium supplementation
Number of subjects: 100
Study 35950283 — intervention group
Group type: EXPERIMENTAL
Intervention: Transradial access (TRA) with patients in foot‐first position (Group A)
Number of subjects: 120
Study 35950283 — intervention group
Group type: EXPERIMENTAL
Intervention: Transradial access (TRA) with patients in conventional head‐first position (Group B)
Number of subjects: 120
Study 35950283 — intervention group
Group type: EXPERIMENTAL
Intervention: Transradial access (TRA) with patients in conventional head‐first position via right radial artery (Group C)
Number of subjects: 120
Study 35950283 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfemoral access (TFA) with patients in conventional head‐first position (Group D)
Number of subjects: 120
Study 34979630 — intervention group
Group type: EXPERIMENTAL
Intervention: FKScope®
Number of subjects: 64
Study 34979630 — intervention group
Group type: COMPARATOR
Intervention: Macintosh
Number of subjects: 64
Study 33009060 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilation
Number of subjects: 102
Study 33009060 — intervention group
Group type: COMPARATOR
Intervention: No Dilation
Number of subjects: 102
Study 34021020 — intervention group
Group type: EXPERIMENTAL
Intervention: GAD-alum therapy with vitamin D supplementation (4 μg GAD-alum intralymphatic injections, 2,000 IE vitamin D daily for 120 days)
Number of subjects: 109
Study 34021020 — intervention group
Group type: EXPERIMENTAL
Intervention: GAD-alum therapy with vitamin D supplementation in HLA DR3-DQ2 genotype (n = 29)
Number of subjects: 109
Study 34021020 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 17)
Number of subjects: 109
Study 34021020 — intervention group
Group type: EXPERIMENTAL
Intervention: GAD-alum therapy with vitamin D supplementation
Number of subjects: 109
Study 36244918 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambient Intelligence monitoring of caregiver activity
Number of subjects: 14
Study 32212866 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftolozane-tazobactam
Number of subjects: 0
Study 35490470 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram model based on gender, age, baseline NIHSS score, hyperhomocysteinemia (HHcy), and multiple lesions
Number of subjects: 191
Study 35490470 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram model
Number of subjects: 191
Study 35283526 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg once daily for 6 weeks
Number of subjects: 0
Study 35283526 — intervention group
Group type: EXPERIMENTAL
Intervention: Rupatadine 10 mg once daily for 6 weeks
Number of subjects: 0
Study 32709912 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week exercise programme
Number of subjects: 22
Study 32709912 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 22
Study 34876454 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF receptor‐1
Number of subjects: 2553
Study 34876454 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF receptor‐2
Number of subjects: 2553
Study 34876454 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of TNF receptor‐1 (≥2992 ng/ml)
Number of subjects: 2553
Study 34876454 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of TNF receptor‐2 (≥11,394 ng/ml)
Number of subjects: 2553
Study 34876454 — intervention group
Group type: COMPARATOR
Intervention: Lower three quartiles of TNF receptor‐1
Number of subjects: 2553
Study 34876454 — intervention group
Group type: COMPARATOR
Intervention: Lower three quartiles of TNF receptor‐2
Number of subjects: 2553
Study 33978597 — intervention group
Group type: EXPERIMENTAL
Intervention: PEARS intervention with low glycemic index dietary intervention and exercise prescription
Number of subjects: 149
Study 33978597 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone app support
Number of subjects: 149
Study 32856448 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical TXA (3 g in 50 ml of saline solution)
Number of subjects: 75
Study 32856448 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous + topical TXA (3 g topical + 2 g in 100 ml of saline solution intravenously)
Number of subjects: 75
Study 32856448 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 75
Study 33678097 — intervention group
Group type: EXPERIMENTAL
Intervention: CinnoVex®
Number of subjects: 41
Study 33678097 — intervention group
Group type: COMPARATOR
Intervention: Avonex®
Number of subjects: 41
Study 34098559 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenapanor
Number of subjects: 47
Study 34098559 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 35922460 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable MTV
Number of subjects: 0
Study 35922460 — intervention group
Group type: COMPARATOR
Intervention: Fixed control MTV
Number of subjects: 0
Study 35922460 — intervention group
Group type: COMPARATOR
Intervention: Unsupervised control MTV
Number of subjects: 0
Study 35790696 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ferric derisomaltose (FDI)
Number of subjects: 0
Study 35790696 — intervention group
Group type: COMPARATOR
Intervention: Saccharated ferric oxide (SFO)
Number of subjects: 0
Study 33941146 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified Accelerated Recovery Protocol (SARP)
Number of subjects: 161
Study 33941146 — intervention group
Group type: COMPARATOR
Intervention: Conventional postoperative care (CC)
Number of subjects: 161
Study 33941146 — intervention group
Group type: EXPERIMENTAL
Intervention: SARP (tolerated)
Number of subjects: 161
Study 33941146 — intervention group
Group type: EXPERIMENTAL
Intervention: SARP (not tolerated)
Number of subjects: 161
Study 36126411 — intervention group
Group type: EXPERIMENTAL
Intervention: SCT630
Number of subjects: 367
Study 36126411 — intervention group
Group type: COMPARATOR
Intervention: adalimumab
Number of subjects: 367
Study 32789929 — intervention group
Group type: EXPERIMENTAL
Intervention: Care for Participation+ (CFP+) intervention
Number of subjects: 0
Study 32789929 — intervention group
Group type: COMPARATOR
Intervention: Participation Mind Map control group
Number of subjects: 0
Study 32789929 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 0
Study 32634486 — intervention group
Group type: EXPERIMENTAL
Intervention: Team Clinic care model
Number of subjects: 0
Study 35798491 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral Approach
Number of subjects: 0
Study 35798491 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial Approach
Number of subjects: 0
Study 34591079 — intervention group
Group type: EXPERIMENTAL
Intervention: TAC 10 mg/mL, 24 hours before surgery
Number of subjects: 40
Study 34591079 — intervention group
Group type: EXPERIMENTAL
Intervention: TAC 10 mg/mL, 1 hour before surgery
Number of subjects: 40
Study 34591079 — intervention group
Group type: EXPERIMENTAL
Intervention: TAC 40 mg/mL, 24 hours before surgery
Number of subjects: 40
Study 34591079 — intervention group
Group type: EXPERIMENTAL
Intervention: TAC 40 mg/mL, 1 hour before surgery
Number of subjects: 40
Study 34591079 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with thickening of the middle ear
Number of subjects: 40
Study 34591079 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall TAC levels in perilymph
Number of subjects: 40
Study 35869315 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-compression
Number of subjects: 495
Study 35869315 — intervention group
Group type: COMPARATOR
Intervention: Radiographer-led compression
Number of subjects: 495
Study 32739562 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Information Preferences (HIPs) regarding diagnosis and treatment details
Number of subjects: 206
Study 32739562 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Information Preferences (HIPs) regarding likely outcome of disease
Number of subjects: 206